This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. By way of ...

Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

Medications for CML directly destroy cancer cells or help the body’s immune system attack cancer cells to prevent them from growing. Medications may not cure CML, so people may need to continue taking ...

Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...

Preclinical data shows TERN-701's superior potency against CML resistance mutations; early clinical trial results indicate promising patient responses. Terns Pharmaceuticals announced promising ...